The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation. IRB Number 16-186
SponsorsThis trial is sponsored by Merck.
Interested in Clinical Trial?
Providers Associated With This Trial
- Jennifer M. Scalici, M.D.Gynecologic OncologistAssociate Professor of Interdisciplinary Clinical Oncology
- Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistInterim Director of Mitchell Cancer Institute; Chief of Gynecologic Oncology Service; Associate Director for Clinical Research, Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology